Latest

University of Galway to Lead New €64.5m Research Ireland Rinn Medical Devices Centre ◆ Chanelle Pharma Renews Historic Partnership with Galway Races Summer Festival 2026 ◆ The Distortion of Irish GDP: How 'Phantom Exports' Are Reshaping the Biopharma Landscape ◆ The Anatomy of a Biologics Warning Letter: Deconstructing Genzyme Waterford’s FDA Audit ◆ The Dublin-Backed Roll-Up Reshaping UK Pharma Packaging: Inside Woodberry's Double Acquisition ◆ The Pill That Promised a Revolution: Why Eli Lilly's Foundayo Is Launching Slower Than Wall Street Expected ◆ Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots ◆ A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals ◆ University of Galway to Lead New €64.5m Research Ireland Rinn Medical Devices Centre ◆ Chanelle Pharma Renews Historic Partnership with Galway Races Summer Festival 2026 ◆ The Distortion of Irish GDP: How 'Phantom Exports' Are Reshaping the Biopharma Landscape ◆ The Anatomy of a Biologics Warning Letter: Deconstructing Genzyme Waterford’s FDA Audit ◆ The Dublin-Backed Roll-Up Reshaping UK Pharma Packaging: Inside Woodberry's Double Acquisition ◆ The Pill That Promised a Revolution: Why Eli Lilly's Foundayo Is Launching Slower Than Wall Street Expected ◆ Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots ◆ A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals ◆

Markets · 15 min delay

NBI4,187.6▲ +1.14%

PFE28.42▼ -0.38%

AZN74.18▲ +0.81%

NVO103.55▲ +2.07%

ROG261.40▼ -0.55%

ABBV174.92▲ +0.29%

EUR/USD1.0842▼ -0.12%

ISEQ9,241.3▲ +0.62%

NBI4,187.6▲ +1.14%

PFE28.42▼ -0.38%

AZN74.18▲ +0.81%

NVO103.55▲ +2.07%

ROG261.40▼ -0.55%

ABBV174.92▲ +0.29%

EUR/USD1.0842▼ -0.12%

Updated 11 Jul 2026 · ClinicalTrials.gov

Clinical Trials in Oxford

← All UK trials

The most recently updated industry-sponsored clinical trials recruiting across the United Kingdom — searchable by condition, sponsor, phase and city. Refreshed daily from the ClinicalTrials.gov registry.

14

Recruiting now

19

Studies tracked

Oxford

Selected city

Recruiting Phase 1

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Eli Lilly and Company · started 2026-05-28

📍 Leeds · Oxford

NCT07101328 on ClinicalTrials.gov ↗

Recruiting Phase 3

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Merck Sharp & Dohme LLC · started 2023-12-13

📍 Bristol · Lancaster · London · Oxford · Newmarket

NCT06136559 on ClinicalTrials.gov ↗

Recruiting Phase 1/Phase 2

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

Multiple Myeloma
GlaxoSmithKline · started 2023-06-14

📍 Leicester · Oxford · Plymouth

NCT05714839 on ClinicalTrials.gov ↗

Recruiting Phase 1/Phase 2

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease
AC Immune SA · started 2022-06-21

📍 Cambridge · Liverpool · London · Oxford · Warrington

NCT05462106 on ClinicalTrials.gov ↗

Recruiting Phase 3

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Non Small Cell Lung Cancer
Merck Sharp & Dohme LLC · started 2024-04-03

📍 Cambridge · Northwood · London · Oxford · Newcastle upon Tyne

NCT06312137 on ClinicalTrials.gov ↗

Recruiting Phase 3

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

Colon Adenocarcinoma, Rectal Adenocarcinoma
Merck Sharp & Dohme LLC · started 2025-07-16

📍 Birmingham · London · Oxford · Coventry · Manchester

NCT06997497 on ClinicalTrials.gov ↗

Recruiting Phase 2

SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

Type 1 Diabetes
SAb Biotherapeutics, Inc. · started 2025-11-25

📍 Cambridge · Cardiff · Edinburgh · Liverpool · London

NCT07187531 on ClinicalTrials.gov ↗

Recruiting Phase 2

Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)

Osteogenesis Imperfecta (OI)
Angitia Incorporated Limited · started 2025-12-12

📍 Cambridge · Edinburgh · London · Oxford

NCT07062588 on ClinicalTrials.gov ↗

Active Phase 2

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

Chronic Kidney Disease
Boehringer Ingelheim · started 2025-07-18

📍 Airdrie · Glasgow · Harrow · High Wycombe · London

NCT06926660 on ClinicalTrials.gov ↗

Recruiting Phase 3

Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
AstraZeneca · started 2026-05-05

📍 Edinburgh · Hampshire · Leeds · London · Manchester

NCT07509151 on ClinicalTrials.gov ↗

Active Phase 3

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Gastric Cancer, Gastroesophageal Junction Cancer
AstraZeneca · started 2024-03-04

📍 Cambridge · London · Manchester · Oxford · Taunton

NCT06346392 on ClinicalTrials.gov ↗

Recruiting Phase 2/Phase 3

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
Exelixis · started 2025-07-21

📍 Liverpool · London · Oxford · Sheffield · Swansea

NCT06943755 on ClinicalTrials.gov ↗

Recruiting

BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

Hypertension, Hypertension, Systolic, Hypertension, Essential
Orchestra BioMed, Inc · started 2023-12-27

📍 London · Oxford · Southhampton

NCT06059638 on ClinicalTrials.gov ↗

Recruiting Phase 3

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

Healthy
Pfizer · started 2025-08-25

📍 Bristol · London · Manchester · Truro · Southampton

NCT07160244 on ClinicalTrials.gov ↗

Recruiting Phase 2

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight

Obesity, Overweight
Boehringer Ingelheim · started 2026-06-30

📍 High Wycombe · Leicester · Middlesbrough · Oxford

NCT07662122 on ClinicalTrials.gov ↗

Active Phase 3

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

Follicular Lymphoma (FL)
Genmab · started 2022-09-20

📍 Plymouth · Glasgow · London · Oxford · Leeds

NCT05409066 on ClinicalTrials.gov ↗

Active Phase 3

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

Myelofibrosis
Geron Corporation · started 2021-04-12

📍 London · Oxford

NCT04576156 on ClinicalTrials.gov ↗

Recruiting Phase 3

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
89bio, Inc. · started 2024-03-13

📍 High Wycombe · Bristol · Glasgow · Hull · London

NCT06318169 on ClinicalTrials.gov ↗

By invitation Phase 3

An Open-label Study of XEN1101 in Epilepsy

Focal Epilepsy, Tonic-Clonic Seizures
Xenon Pharmaceuticals Inc. · started 2023-04-25

📍 Leeds · Cardiff · Birmingham · London · Oxford

NCT05718817 on ClinicalTrials.gov ↗

No trials match your search.

Browse by city

London · 118 Manchester · 30 Glasgow · 27 Cambridge · 27 Birmingham · 24 Leicester · 23 Bristol · 23 Leeds · 22 Sutton · 19 Oxford · 19 Liverpool · 18 Edinburgh · 15 Nottingham · 14 Cardiff · 14 Newcastle upon Tyne · 13 Sheffield · 12

Browse by condition

Obesity · 5 Chronic Lymphocytic Leukemia · 5 Cancer · 4 Breast Neoplasms · 3 Non-small Cell Lung Cancer · 3 Small Lymphocytic Lymphoma · 3 Multiple Myeloma · 3 Hypertension · 3 Heart Failure · 3 Triple Negative Breast Neoplasms · 2 Lymphoma, Non-Hodgkin · 2 Lymphoma, Follicular · 2 Lymphoma, Large B-Cell, Diffuse · 2 Gastric Cancer · 2 Metastatic Prostate Cancer · 2 Overweight · 2

Cite this page

Priya Life Science (2026). Clinical Trials in the UK Tracker. Available at: https://priyalifescience.com/clinical-trials-uk/city/oxford (Accessed: 11 July 2026).

Source: ClinicalTrials.gov, U.S. National Library of Medicine — industry-sponsored studies in a recruiting status with at least one UK site, most recently updated first, refreshed daily. This is a curated slice of the registry, not every UK trial; UK studies may also be registered on ISRCTN. Listing here is informational and not medical advice; eligibility is determined by each study team. Patients should discuss participation with their clinician. Compare pay for the teams running these studies in our UK Pharma Salary Guide, or see our Ireland, EU and USA trackers.